2021 Update for the Diagnosis and Management of Acute Coronary Syndromes for the Perioperative Clinician

Kunkel, Katherine; Lemor, Alejandro; Mahmood, Shazil; Villablanca, Pedro; Ramakrishna, Harish

doi:10.1053/j.jvca.2021.07.032

Cited by 6 publications

(4 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rupture of this plaque in some instances while physiologic stress in the form of trauma, blood loss, anemia or infection, increasing the demand of 18 blood supply may lead to myocardial infarction. Diagnosis of acute myocardial infarction is based upon appearance of cardiac biochemical markers in addition to clinical symptoms and classical ECG 16,17 findings.…”

Section: Discussionmentioning

confidence: 99%

Factors Impacting Myocardial Infarction in Young Population; An Institution Based Experience

Fatima,

Athar Nayeem,

Afia Sarwar

et al. 2023

J Allam Iqbal Med Coll Lahore

View full text Add to dashboard Cite

ABSTRACT Objective: To determine the frequency of contributing factors in Myocardial Infarction in young population Study design: Descriptive, Cross-sectional study Study was conducted over a period of six months in Medical Unit-II of Services Hospital, Lahore. Materials & Methods: A total population of 149 young patients irrespective of their gender with age range from 15 to 45 years and suffering from myocardial infarction were included in this study. Relevant information comprising of presence or absence of Hypertension, Diabetes, Smoking, Dyslipidemia, Obesity, Hyperuricemia, and Family history of these selected cases were recorded in the data collection proforma and patients’ confidentiality was ensured. Results: Out of 149 patients, 101 (67.79%) were males and 48 (32.21%) were females with male to female ratio of 2.1:1. Age range in this study was from 15 to 45 years with mean age of 34.68 ± 6.93 years. Majority of the patients; 80 (53.69%) were between 30 to 45 years of age. Hypertension was reported in 57 (38.26%), Diabetes Mellitus in 28 (18.79%), smoking in 61 (40.94%), dyslipidemia in 80 (53.69%), obesity in 20 (13.42%), hyperuricemia in 21 (14.09%) and positive family history was seen in 30 (20.13%) patients. Conclusion: This study concluded that Hypertension, Diabetes, Smoking and Dyslipidemia constitute the common and most important contributing factors of Myocardial Infarction(MI) in young patients aged between 15 to 45 years. Keywords: Myocardial Infarction, young patients, factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors Impacting Myocardial Infarction in Young Population; An Institution Based Experience

Fatima,

Athar Nayeem,

Afia Sarwar

et al. 2023

J Allam Iqbal Med Coll Lahore

View full text Add to dashboard Cite

show abstract

“…All participants, investigators, and analyzers were blinded to the study treatment protocol. Additionally, all patients were supported and received the recommended medical treatments, including anti‐diabetic drugs, angiotensin‐converting enzyme inhibitors, selective beta‐blockers, anti‐platelet medications (aspirin and clopidogrel), and high doses of statin (atorvastatin 80 mg) 8,15 …”

Section: Methodsmentioning

confidence: 99%

Three months of combination therapy with nano‐curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double‐blinded, placebo‐controlled clinical trial

et al. 2022

View full text Add to dashboard Cite

Diabetes is one of the most common chronic diseases worldwide. Systemic inflammation (high-sensitivity C-reactive protein (hs-CRP)) and lipid metabolism disruption (lipoprotein A, LipoPr (a)) play a critical role in developing and progressing atherosclerosis and acute coronary syndrome in diabetic patients. The anti-oxidant and anti-inflammatory effects of curcumin have been emphasized previously. Therefore, we aimed to evaluate the impact of nano-curcumin on cardiovascular risk factors in type 2 diabetic patients with mild to moderate coronary artery disease (CAD). We performed a randomized, double-blinded, placebo-controlled clinical trial with type 2 diabetic patients (n = 64), and mild to moderate CAD (<70% stenosis in angiography). The patients received nano-curcumin (80 mg/day) or placebo along with optimal medications for 90 days. The biofactors, including hs-CRP and LipoPr (a), and lipid profile, were measured at the admission of patients and end of the study. Nano-curcumin significantly mitigated the hs-CRP and LipoPr (a) levels following 90 days of treatment (P < 0.001 and P = 0.043, respectively). In addition, the mean percentage of change (%Δ) in the hs-CRP and LipoPr (a) levels were meaningfully reduced in the nano-curcumin group compared to the placebo group (P < 0.001 and P = 0.007, respectively). Surprisingly, nanocurcumin notably propagated the number of patients with mild (34.35%) and moderate (62.5%) hs-CRP level category and strikingly diminished the number of patients with severe hs-CRP level category (3.125%) compared to the placebo group (P = 0.016). Nano-curcumin (80 mg/day) might prevent atherosclerosis

show abstract

“…Acute myocardial infarction (AMI) is the dominant cause of global death [ 1 ]. Reperfusion is the standardized therapy for AMI, but the restoration of blood further aggravates cardiomyocyte death.…”

Section: Introductionmentioning

confidence: 99%

SIRT3 and RORα are two prospective targets against mitophagy during simulated ischemia/reperfusion injury in H9c2 cells

Wu,

Yang,

Lin

et al. 2024

Heliyon

View full text Add to dashboard Cite

2021 Update for the Diagnosis and Management of Acute Coronary Syndromes for the Perioperative Clinician

Cited by 6 publications

References 104 publications

Factors Impacting Myocardial Infarction in Young Population; An Institution Based Experience

Factors Impacting Myocardial Infarction in Young Population; An Institution Based Experience

Three months of combination therapy with nano‐curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double‐blinded, placebo‐controlled clinical trial

SIRT3 and RORα are two prospective targets against mitophagy during simulated ischemia/reperfusion injury in H9c2 cells

Contact Info

Product

Resources

About